KDR

(redirected from VEGFR2)
Also found in: Acronyms.

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
The content of CD34 and VEGFR2 proteins in the right white matter of premature brain was also determined by Western blot assays.
10 (Molecular Operating Environment), computational docking was performed to explore molecular interactions between VEGFR2 and RA.
The researchers examined mice that were lacking a particular part of the NRP1 molecule that transports VEGF and VEGFR2 to a signaling center inside blood vessel walls.
So this longitudinal study attempted to determine the extent of association of anaerobic glycolysis and related biochemical phenomena with the altered expression of VEGF, VEGFR2, MMP2 and MMP9 at the time of onset of DR.
Stimulation of VEGFR2 in bone marrow results in MMP-9 activation, which in turn cleaves membrane-bound KitL to generate the soluble KitL (SCF or steel factor) (Heissig et al.
VEGF/ VEGFR2 directly regulates tumor angiogenesis and also works as an essential autocrine/paracrine process for cancer cell novel antagonists, PEG-LPrAs, significantly impaired the growth of breast tumors and reduced the levels of VEGF/VEG-FR2.
PTK/ZK blocks the signaling of all known VEGF pathways at the receptors (VEGFR1, VEGFR2, and VEGFR3) regardless of the growth factor (VEGF A-E).
CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.
EPIGENOMIC REGULATION OF VEGFR2 BY LEPTIN-OTCH SIGNALING CROSS-TALK IN MAMMARY CANCER CELLS, Shanchun Guo *, Yanbo Xu, Miles Fuller and Ruben R.
vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor, Fms-like tyrosine kinase-3, colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor.
The agent has been confirmed via X-ray crystal structural analysis to indicate a new binding mode (Type V) to VEGFR2, and exhibits rapid and potent inhibition of kinase activity, according to kinetic analysis.